Objective:To observe the clinical efficacy of Peiyuan Chuzhuo decoction and Sorafenib on moderate or advanced liver cancer.Methods:60 cases of patients with moderate or advanced liver cancer were selected according to the eligibility criteria and randomly divided into two groups,30 cases in each group.The control group was treated with Sorafenib and Kushen injection,while the treatment group was treated plus with Peiyuan Chuzhuo decoction on the basis of control group.The course of treatment was 3 months.Results:The treatment group was better than control group in the improvement of TCM syndrome scores such as chest distress with sighing frequehtly,depressed mood,abdominal distension,diarrhea with loose stool,spiritlessness with weakness,anorexia,etc.(P＜0.05);in addition,the treatment group was obviously better than control group in the improvement of lymphocyte subset index level and life-quality score.In the treatment group,the disease control rate was slightly higher than those of control group and AFP index level was lower than those of control group,but the difference was not statistically significant.The incidence rate of adverse reactions of treatment group was 36.67％,which was lower than 76.67％of control group(P＜0.01).Conclusion:The clinical efficacy of Peiyuan Chuzhuo decoction and Sorafenib on moderate or advanced liver cancer is significant,which can improve patients'immune function and enhance the quality of life.
关键词
肝癌/培元黜浊汤/索拉非尼/中西医结合疗法
Key words
liver cancer/Peiyuan Chuzhuo decoction/Sorafenib/integrated therapy of traditional Chinese and western medicine
维普
万方数据